Literature DB >> 22232082

Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation.

Hanan E Shamseldin1, Mohamed Elfaki, Fowzan S Alkuraya.   

Abstract

Background Fanconi anaemia (FA) is a group of disorders characterised by progressive bone marrow failure and a characteristic but variable craniofacial and skeletal involvement. Recessive mutations in any of 15 genes linked to FA lead to the pathognomonic increased susceptibility to double-strand DNA breaks. Methods Autozygome and exome analysis of a patient with classic FA phenotype Results The authors identified a novel truncating mutation in XRCC2. Consistent with the proposed causal link to FA, this gene is an essential non-redundant component of the RAD51 family of homologous repair proteins and its deficiency in a murine model has been shown to lead to a highly similar phenotype to that of this patient both at the cellular and organismal level. Conclusion This study implicates XRCC2 in the pathogenesis of FA and calls for further investigation of the potential contribution of XRCC2 mutations to the overall mutational load of FA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232082     DOI: 10.1136/jmedgenet-2011-100585

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  34 in total

Review 1.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

Authors:  Hyungjin Kim; Alan D D'Andrea
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

Review 2.  Applications of high-throughput DNA sequencing to benign hematology.

Authors:  Vijay G Sankaran; Patrick G Gallagher
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

Review 3.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 4.  Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers.

Authors:  Ronald S Cheung; Toshiyasu Taniguchi
Journal:  Int J Hematol       Date:  2017-06-19       Impact factor: 2.490

5.  Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.

Authors:  Suhair Lolas Hamameh; Paul Renbaum; Lara Kamal; Dima Dweik; Mohammad Salahat; Tamara Jaraysa; Amal Abu Rayyan; Silvia Casadei; Jessica B Mandell; Suleyman Gulsuner; Ming K Lee; Tom Walsh; Mary-Claire King; Ephrat Levy-Lahad; Moein Kanaan
Journal:  Int J Cancer       Date:  2017-05-19       Impact factor: 7.396

6.  Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia.

Authors:  Kerstin Knies; Shojiro Inano; María J Ramírez; Masamichi Ishiai; Jordi Surrallés; Minoru Takata; Detlev Schindler
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 7.  The application of next-generation sequencing in the autozygosity mapping of human recessive diseases.

Authors:  Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2013-08-02       Impact factor: 4.132

Review 8.  Diseases associated with defective responses to DNA damage.

Authors:  Mark O'Driscoll
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

9.  Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.

Authors:  Helmut Hanenberg; Paul R Andreassen; Jung-Young Park; Elizabeth L Virts; Anna Jankowska; Constanze Wiek; Mohamed Othman; Sujata C Chakraborty; Gail H Vance; Fowzan S Alkuraya
Journal:  J Med Genet       Date:  2016-05-20       Impact factor: 6.318

10.  Mutations in CENPE define a novel kinetochore-centromeric mechanism for microcephalic primordial dwarfism.

Authors:  Ghayda M Mirzaa; Benjamin Vitre; Gillian Carpenter; Iga Abramowicz; Joseph G Gleeson; Alex R Paciorkowski; Don W Cleveland; William B Dobyns; Mark O'Driscoll
Journal:  Hum Genet       Date:  2014-04-20       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.